Predicting Thrombocytopenia

Preclinical Models of Nicotinamide Phosphoribosyltransferase Inhibitor-Mediated Hematotoxicity and Mitigation by Co-treatment with Nicotinic Acid,“Tarrant J.M.,1* Dhawan P.,Singh J.,1,2  Zabka T.S.,Clarke E.,Dos Santos G.,Dragovich P.S.,Sampath D.,Lin T.,McCray B.,La N.,1 Nguyen T.,1 Kauss A.,1 Dambach D.,1 Misner D.L.,1 Diaz D.,1 Uppal H.,1,6. Toxicology Mechanisms and Methods: 1-11, April 20 2015 (early online). 1Department of Safety Assessment, Genentech Inc, South San Francisco, CA, USA, 2Retrophin Inc, Cambridge, MA, USA, 3ReachBio, Seattle, WA, USA, 4Department of Discovery Chemistry and 5Department of Translational Oncology, Genentech Inc, South San Francisco, CA, USA, and 6Medivation, San Francisco, CA, USA.
Chronic Myeloid Leukemia (Clinical Trail Samples) “Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323,”Shah N.P.,1 Cortes J.E.,2 Martinelli G.,3 Smith B.D.,4 Clarke E.,5 Copland M.,6 Strauss L.,7 Talpaz M.,8. Blood: 4539-4539, 124 (21). 1University of California, San Francisco, CA, USA; 2The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3University of Bologna, Bologna, Italy; 4Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; 5ReachBio LLC, Seattle, WA, USA; 6University of Glasgow, Glasgow, United Kingdom; 7Bristol-Myers Squibb, Wallingford, CT, USA; 8The University of Michigan Hospital and Health Systems-Comprehensive Cancer Center, Ann Arbor, MI, USA.
Mesenchymal Stem Cells Mesenchymal Stem Cell Mechanics from the Attached to the Suspended State,” Maloney J.M.,1 Nikova D.,1 Lautenschläger F.,2 Clarke E.,3 Langer R.,4,5 Guck J.,2 Van Vliet K.J.,1,5 Biophysical Journal, 99: 2479-2487, October 2010. 1Department of Materials Science and Engineering, 4Department of Chemical Engineering, and 5Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts; 2Department of Physics, Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom; and 3ReachBio, Seattle, Washington.
Predicting Myelotoxicity Predicting Drug-Induced Myelotoxicity,” Clarke E.,1 Atkinson E.,2 Genetic Engineering & Biotechnology News, 30(4): 14-15, February 15 2010.1ReachBio LLC, 2 BroadReach Biosystems
Stem Cell Sciences Introduction to Stem Cell Science,” Ennis C., Clarke E.,1 Lannon, C., Atkinson E.,2 Quantum Scientific Publishing, 1-284, 2012.  1ReachBio LLC, 2 BroadReach Biosystems.
 CFC Assays  "CoREST Complex-Selective Histone Deacetylase Inhibitors Show Prosynaptic Effects and an Improved Safety Profile To Enable Treatment of Synaptopathies," Fuller N., Pirone A., Lynch B., Hewitt M., Quinton M., McKee T., and Ivarsson M.,  ACS Chem. Neurosci. 10-21, 2018. Rodin Therapeutics, Cambridge, Massachusetts.
BFU-E Assays "Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2," Shearstone J., Golonzhka O., Chonkar A., Tamang D., van Duzer J., Jones S., Jarpe M., PLoS One. April 13, 2016. Acetylon Pharmaceuticals, Boston, Massachusetts.